Literature DB >> 16788796

[Benign prostatic syndrome (BPS). Ablative treatments].

O Reich1, M Seitz, C Gratzke, B Schlenker, A Bachmann, C Stief.   

Abstract

Today, the surgical treatment of the benign prostatic syndrome (BPS) often follows a course of drug treatment. Besides conventional transurethral resection of the prostate (TURP), which has represented the standard therapeutic option for decades, and its in part significant modifications ("vaporizing resection"; bipolar resection), much of the interest has shifted to alternative instrumental procedures like transurethral microwave therapy (TUMT), transurethral needle ablation of the prostate (TUNA) or several laser techniques. By reviewing the current literature, preferably from randomized controlled trials, these different procedures are critically assessed. Moreover, the present role of open prostatectomy is discussed.

Entities:  

Mesh:

Year:  2006        PMID: 16788796     DOI: 10.1007/s00120-006-1039-1

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  83 in total

1.  In vitro comparison of transurethral vaporization of the prostate (TUVP), resection of the prostate (TURP), and vaporization-resection of the prostate (TUVRP).

Authors:  Oliver Reich; Stefan Corvin; Ralph Oberneder; Ronald Sroka; Rolf Muschter; Alfons Hofstetter
Journal:  Urol Res       Date:  2002-03

2.  Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers.

Authors:  Alexandre R Zlotta; Xenofon Giannakopoulos; Odd Maehlum; Tonnes Ostrem; Claude C Schulman
Journal:  Eur Urol       Date:  2003-07       Impact factor: 20.096

3.  Gyrus bipolar versus standard monopolar transurethral resection of the prostate: a randomized prospective trial.

Authors:  Marco de Sio; Riccardo Autorino; Giuseppe Quarto; Rocco Damiano; Sisto Perdonà; Giuseppe di Lorenzo; Salvatore Mordente; Massimo D'Armiento
Journal:  Urology       Date:  2006-01       Impact factor: 2.649

4.  Laparoscopic retropubic simple prostatectomy.

Authors:  René Sotelo; Massimiliano Spaliviero; Alejandro Garcia-Segui; Waleed Hasan; John Novoa; Mihir M Desai; Jihad H Kaouk; Inderbir S Gill
Journal:  J Urol       Date:  2005-03       Impact factor: 7.450

5.  Retropubic transvesical prostatectomy for significant prostatic enlargement must remain a standard part of urology training.

Authors:  Christoph Adam; Alfons Hofstetter; Jörg Deubner; Dirk Zaak; Rolf Weitkunat; Michael Seitz; Peter Schneede
Journal:  Scand J Urol Nephrol       Date:  2004

6.  Photoselective vaporization (PVP) versus transurethral resection of the prostate (TURP): a prospective bi-centre study of perioperative morbidity and early functional outcome.

Authors:  Alexander Bachmann; Leander Schürch; Robin Ruszat; Stephen F Wyler; Hans-Helge Seifert; Alexander Müller; Kurt Lehmann; Tullio Sulser
Journal:  Eur Urol       Date:  2005-07-18       Impact factor: 20.096

7.  A cost comparison of medical management and transurethral needle ablation for treatment of benign prostatic hyperplasia during a 5-year period.

Authors:  M J Naslund; A M Carlson; M J Williams
Journal:  J Urol       Date:  2005-06       Impact factor: 7.450

8.  A randomized trial comparing holmium laser enucleation of the prostate with transurethral resection of the prostate for the treatment of bladder outlet obstruction secondary to benign prostatic hyperplasia in large glands (40 to 200 grams).

Authors:  A H H Tan; P J Gilling; K M Kennett; C Frampton; A M Westenberg; M R Fraundorfer
Journal:  J Urol       Date:  2003-10       Impact factor: 7.450

9.  Long-term results following transurethral resection of the prostate.

Authors:  U Zwergel; B Wullich; U Lindenmeir; V Rohde; T Zwergel
Journal:  Eur Urol       Date:  1998       Impact factor: 20.096

10.  Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial.

Authors:  Brian Hill; William Belville; Reginald Bruskewitz; Muta Issa; Ramon Perez-Marrero; Claus Roehrborn; Martha Terris; Michael Naslund
Journal:  J Urol       Date:  2004-06       Impact factor: 7.450

View more
  5 in total

1.  [Diode laser. Ex vivo studies on vaporization and coagulation characteristics].

Authors:  M Seitz; A Ackermann; C Gratzke; B Schlenker; R Ruszat; A Bachmann; C Stief; O Reich; R Sroka
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

2.  [Transurethral enucleation of the prostate with the holmium: YAG laser system: how much power is necessary?].

Authors:  J Rassweiler; M Roder; M Schulze; R Muschter
Journal:  Urologe A       Date:  2008-04       Impact factor: 0.639

3.  Ex vivo and in vivo investigations of the novel 1,470 nm diode laser for potential treatment of benign prostatic enlargement.

Authors:  Michael Seitz; Robin Ruszat; Thomas Bayer; Derya Tilki; Alexander Bachmann; Christian Stief; Ronald Sroka; Oliver Reich
Journal:  Lasers Med Sci       Date:  2008-08-07       Impact factor: 3.161

4.  High-power diode laser at 980 nm for the treatment of benign prostatic hyperplasia: ex vivo investigations on porcine kidneys and human cadaver prostates.

Authors:  Michael Seitz; Oliver Reich; Christian Gratzke; Boris Schlenker; Alexander Karl; Markus Bader; Wael Khoder; Florian Fischer; Christian Stief; Ronald Sroka
Journal:  Lasers Med Sci       Date:  2008-02-13       Impact factor: 3.161

5.  Outcome of 980 nm diode laser vaporization for benign prostatic hyperplasia: A prospective study.

Authors:  M Hammad Mithani; Salman El Khalid; Shariq Anis Khan; Imran Sharif; Adnan Siddiq Awan; Shoaib Mithani; Irfan Majeed
Journal:  Investig Clin Urol       Date:  2018-10-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.